Denali Therapeutics (BSP:D2NL34) DeferredTaxAndRevenue: R$102.35 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:D2NL34 Denali Therapeutics Inc BSP:D2NL34
6 GF Score
Price R$27.06
! 6 Warning Signs
View Full Analysis

What is Denali Therapeutics DeferredTaxAndRevenue?

Denali Therapeutics BSP:D2NL34 6 DeferredTaxAndRevenue is R$102.35 Mil as of Jun. 2026. GuruFocus rates BSP:D2NL34 with a GF Score™ of 6/100. The stock has 6 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Denali Therapeutics's current deferred tax and revenue for the quarter that ended in Jun. 2026 was R$102.35 Mil.

Denali Therapeutics DeferredTaxAndRevenue Related Terms

Denali Therapeutics DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Denali Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Denali Therapeutics DeferredTaxAndRevenue Chart

Denali Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,811.27 1,521.44 0.00 86.20 115.12

Denali Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 110.15 121.10 115.12 79.05 102.35
BSP:D2NL34
6GF Score
Denali Therapeutics Inc BSP:D2NL34
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of R$102.35 Mil mean?
Denali Therapeutics (BSP:D2NL34) has a DeferredTaxAndRevenue of R$102.35 Mil as of Jun. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Denali Therapeutics.
Is Denali Therapeutics' DeferredTaxAndRevenue too high?
Denali Therapeutics' current DeferredTaxAndRevenue is R$102.35 Mil. Overall, Denali Therapeutics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' DeferredTaxAndRevenue compare to RCUS and ALMS?
Denali Therapeutics' DeferredTaxAndRevenue of R$102.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Denali Therapeutics. Denali Therapeutics's current DeferredTaxAndRevenue is R$102.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Denali Therapeutics (BSP:D2NL34) has a current DeferredTaxAndRevenue of R$102.35 Mil. The current DeferredTaxAndRevenue is R$102.35 Mil. Denali Therapeutics' overall GF Score™ is 6/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Denali Therapeutics (BSP:D2NL34), the current DeferredTaxAndRevenue is R$102.35 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Denali Therapeutics Business Description

Other Exchanges DNLI:USA4DN:Germany
Address 161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
6GF Score

Get the complete analysis for BSP:D2NL34

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$27.06
Price